Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
2C-xlsd, psilocybin, mescaline +5 morelsd, psilocybin, mescaline, 2c-b, 2c-e, 2c-i, dom, doi show less
2C-D
4-methyl-2,5-dimethoxyphenethylamine
2C-D (2,5-dimethoxy-4-methylphenethylamine) is a synthetic psychedelic of the phenethylamine class. It is the least potent member of the 2C series — the phenethylamine counterpart of DOM. It activates serotonin receptors in the brain,[1][2][3] producing mild perceptual and cognitive shifts.
2C-D (2,5-dimethoxy-4-methylphenethylamine) is a synthetic psychedelic of the phenethylamine class. It is the least potent of the 2C series — the phenethylamine counterpart of DOM, with a far milder and briefer profile. 2C-D is a weak agonist at serotonin 5-HT₂A receptors,[1] producing its effects by enhancing excitatory signaling in cortical neurons.[2][3]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
2C-xlsd, psilocybin, mescaline +5 morelsd, psilocybin, mescaline, 2c-b, 2c-e, 2c-i, dom, doi show less
First synthesized in 1970,[4] 2C-D was characterized by Alexander Shulgin through self-experiments and documented in PiHKAL as entry #23.[5] Shulgin described it as "pharmacological tofu" — a mild potentiator used alongside other substances rather than a standalone psychedelic. It was placed in Schedule I in the United States in 2012[6] and is controlled in most major jurisdictions.
Subjective effects include mild sensory enhancement, mood elevation, facilitated communication, and subtle perceptual shifts.[5] The experience is defined by its transparency — a gentle broadening of awareness that amplifies mood and environment rather than imposing its own character. Nausea during onset and restlessness are common.
2C-D produces no physical dependence, and no fatality attributed to it alone appears in the medical literature.[7] The main danger is combining it with SSRIs or MAOIs — 2C-D both activates serotonin receptors and inhibits the enzyme that clears serotonin,[8] which can trigger a dangerous overload. Understanding rests almost entirely on Shulgin's self-experiments and class-level data; no human clinical studies have been conducted.
History[edit]
Discovery
2C-D was first synthesized by Beng T. Ho and colleagues in 1970.[4] Alexander Shulgin began self-testing it at sub-threshold doses as early as 1964 and reached active doses by 1974–1975.[4]
Clinical and cultural significance
Under the designation LE-25, German psychiatrist Hanscarl Leuner used 2C-D as an adjunct in psycholytic psychotherapy — not as a primary agent, but to extend and modulate the effects of co-administered substances.[5][9] Shulgin documented it as entry #23 in PiHKAL,[5] characterizing it as "pharmacological tofu" — a compound whose primary value was potentiating other substances.
Prohibition
2C-D remained unscheduled in the United States for over four decades. The Synthetic Drug Abuse Prevention Act of 2012 explicitly placed it in Schedule I.[6] The United Kingdom had already classified it as Class A under a 2002 amendment covering all PiHKAL phenethylamines.[4]
The name 2C-D follows Shulgin's naming convention: "2C" denotes a phenethylamine with a two-carbon side chain, distinguishing it from the α-methylated DOx amphetamines, while "D" serves as a mnemonic shorthand. The compound's reputation as "pharmacological tofu" — Shulgin's characterization of its bland, potentiating character — has defined its identity through decades of psychedelic discourse, making 2C-D one of the few substances better known for what it lacks than what it produces.
Chemistry[edit]
Structural class
2C-D belongs to the 2C family of phenethylamines — compounds built on a 2,5-dimethoxyphenethylamine backbone with a variable group at the 4-position.[10]
The 4-position carries a methyl group — the smallest in the 2C series — which is why 2C-D is less potent than relatives like 2C-B (4-bromo) and 2C-I (4-iodo).[11] It is the structural phenethylamine counterpart of DOM, with the molecular formula C₁₁H₁₇NO₂ (195.26 g/mol).
Molecular properties
| Molecular formula | C₁₁H₁₇NO₂ |
| Molecular weight | 195.26 g/mol |
Pharmacology[edit]
Mechanism of action
2C-D activates serotonin receptors in the prefrontal cortex,[11][3] increasing excitatory signaling in a way that produces the perceptual and cognitive shifts of psychedelic states.[2] It is classified as a weak agonist at these receptors,[1] making it less potent than 2C-B, 2C-I, and 2C-E. Studies in animals confirm it engages the same serotonergic pathway as other classical psychedelics.[12][13]
MAO inhibition
2C-D also inhibits monoamine oxidase (MAO) — the enzyme that breaks down serotonin, dopamine, and norepinephrine.[8] When this enzyme is blocked, monoamine levels rise, which can cause agitation, rapid heart rate, elevated blood pressure, and seizures.[8]
Pharmacokinetics
No pharmacokinetic data specific to 2C-D have been published.[7] The 2C series broadly is thought to be metabolized by removal of methoxy groups from the ring, primarily through MAO-A,[7] with possible involvement of liver enzymes.[14] Effects begin within 15–45 minutes of oral ingestion and last 4–6 hours[5] — figures from Shulgin's self-experiments, not clinical studies.
Neuroscience[edit]
Where it acts
2C-D activates serotonin receptors concentrated in the prefrontal cortex,[2][3] increasing excitatory signaling and disrupting the brain's normal filtering of sensory and cognitive input. Because 2C-D binds weakly, these disruptions are proportionally milder than those produced by more potent psychedelics like LSD or psilocybin.
Why it matters
One theory proposes that psychedelics increase the disorder of brain activity, expanding the range of accessible conscious states.citation needed A related model suggests they loosen the brain's reliance on prior expectations, allowing more cognitive flexibility.citation needed 2C-D's reputation as a mild potentiator — amplifying other substances without strongly defining the experience — may represent a partial version of this effect at standard doses.
- Does 2C-D produce measurable disruption of default mode network activity at standard oral doses, or is its receptor binding too weak to reach the threshold for network-level effects?
- Does the "potentiator" effect described by Shulgin reflect sub-threshold receptor occupancy that synergizes with co-administered psychedelics?
- How does the absence of the α-methyl group (distinguishing 2C-D from DOM) affect brain penetration, receptor residence time, and the character of neural effects?
Subjective Effects[edit]
The defining quality of 2C-D is transparency. At standard doses, the experience is a gentle broadening of perceptual and emotional range — colors may sharpen, mood lifts, conversation feels easier — but the compound imposes almost no pharmacological signature of its own.[5] Set and setting shape the experience more than the substance does.
Compared to 2C-B — the most widely used 2C-series compound — 2C-D is substantially less visually active, less empathogenic, and more cognitively clear. Where 2C-B produces a distinct sensory and emotional push, 2C-D operates closer to a psychedelic threshold — more like an enhanced mood state than a classical psychedelic experience.
First synthesized by Ho and colleagues in 1970 and subsequently characterized by Alexander Shulgin through self-experiments beginning in the mid-1960s,[4] 2C-D was documented as entry #23 in PiHKAL.[5] Shulgin described it as "pharmacological tofu" — a compound with minimal standalone character whose primary application was potentiating co-administered substances. It was placed in Schedule I in the United States in 2012.[6]
Subjective effects include mild sensory enhancement, facilitated communication, mood elevation, and subtle perceptual shifts.[5] The experience is defined by its transparency — a gentle broadening of perceptual and emotional range that amplifies set and setting rather than imposing a pharmacological signature of its own. Nausea during onset and restlessness are common unsought effects.
No physical dependence has been documented for any 2C-series compound, and no fatality attributable to 2C-D alone appears in the clinical literature.[7] 2C-D demonstrates monoamine oxidase inhibitory potential,[8] creating compounding serotonergic risk when combined with SSRIs, MAOIs, or other serotonin-elevating substances. No clinical studies have been conducted; the current understanding rests on Shulgin's bioassays, class-level pharmacology, and a single in vitro MAO inhibition study.
History[edit]
Discovery
2C-D was first synthesized by Beng T. Ho and colleagues at the Texas Research Institute of Mental Sciences in 1970.[4] Alexander Shulgin began self-testing the compound at sub-threshold doses as early as 1964, reaching active doses by 1974–1975.[4] The human psychopharmacology of 2C-D was first described by Shulgin and Michael Carter in 1975, though this paper has not been located in indexed databases.
Clinical and cultural significance
Under the designation LE-25, 2C-D was explored by German psychiatrist Hanscarl Leuner as an adjunct in psycholytic psychotherapy — used to extend and modulate the effects of co-administered substances rather than as a primary agent.[5][9] Shulgin later documented the compound as entry #23 in PiHKAL,[5] providing a complete synthesis route, a dose range of 20–60 mg oral, and bioassay narratives describing a subtle, communication-facilitating experience with mildly psychedelic character emerging only at the upper dosage extreme.
Prohibition
2C-D remained unscheduled in the United States for over four decades following its synthesis. The Synthetic Drug Abuse Prevention Act of 2012, enacted as part of FDASIA (P.L. 112-144), explicitly placed 2C-D in Schedule I of the Controlled Substances Act.[6] The United Kingdom had already classified it as Class A, Schedule 1 under a 2002 amendment encompassing all PiHKAL phenethylamines.[4]
The name 2C-D follows Shulgin's naming convention: "2C" denotes a phenethylamine with a two-carbon side chain, distinguishing it from the α-methylated DOx amphetamines, while "D" serves as a mnemonic shorthand. The compound's reputation as "pharmacological tofu" — Shulgin's characterization of its bland, potentiating character — has defined its identity through decades of psychedelic discourse, making 2C-D one of the few substances better known for what it lacks than what it produces.
Chemistry[edit]
Structural class
2C-D belongs to the 2C family of substituted phenethylamines — compounds sharing a 2,5-dimethoxyphenethylamine backbone with a variable substituent at the 4-position of the aromatic ring. The "2C" designation refers to the two-carbon ethylamine side chain, distinguishing these compounds from their α-methylated amphetamine counterparts (the DOx series). 2C-D bears a 4-methyl group — the smallest commonly encountered in the 2C family — making it the structural phenethylamine counterpart of DOM.[10]
This minimal substituent is directly responsible for 2C-D's low potency relative to more heavily substituted relatives like 2C-B (4-bromo) and 2C-I (4-iodo).[11] In the 2C series, larger and more lipophilic 4-position groups generally confer stronger receptor binding and greater psychedelic potency.
Molecular properties
| Molecular formula | C₁₁H₁₇NO₂ |
| Molecular weight | 195.26 g/mol |
The molecule consists of a phenethylamine core with methoxy groups at the 2- and 5-positions and a methyl group at the 4-position. The two methoxy groups occupy a para-arrangement relative to each other, with the 4-methyl group positioned between them on the ring. As a primary amine with no chirality centers, 2C-D is achiral and does not exhibit stereoisomerism.
Physical properties
2C-D is most commonly encountered as the hydrochloride salt, with a reported melting point of 213–214°C.[9] No published data on solubility, stability, or degradation pathways specific to 2C-D were identified in the literature.
Pharmacology[edit]
Mechanism of action
2C-D produces its psychedelic effects through agonism at serotonin 5-HT₂A receptors,[11][3] the principal molecular target for classical hallucinogenic phenethylamines and tryptamines. Activation of these receptors on neurons in the prefrontal cortex increases excitatory signaling, a mechanism believed to underlie the perceptual and cognitive changes characteristic of psychedelic states.[2]
2C-D also acts at 5-HT₂C receptors,[1] though the contribution of this target to its subjective effects has not been established. The compound is classified as a "weak" serotonin receptor agonist at both targets,[1] placing it below more potent 2C-series compounds such as 2C-B, 2C-I, and 2C-E, which carry larger substituents at the 4-position.
Drug discrimination studies in rats trained to recognize LSD have confirmed that 2C-D engages the same serotonergic pathway,[12][13] supporting a shared hallucinogenic mechanism across the class.
MAO inhibition
2C-D demonstrates inhibitory activity against monoamine oxidase (MAO), the enzyme system responsible for breaking down serotonin, dopamine, and norepinephrine.[8] Wagmann et al. evaluated 17 psychoactive 2C-series compounds for MAO-A and MAO-B inhibition, finding activity across the class.[8] This property is clinically relevant: MAO inhibition raises brain monoamine levels, which can contribute to agitation, nausea, rapid heart rate, elevated blood pressure, and seizures.[8]
Pharmacokinetics
No pharmacokinetic data specific to 2C-D exist in the published literature. Bioavailability, plasma half-life, and clearance pathways have not been characterized in humans. For the 2C series broadly, metabolism is believed to proceed through removal of methoxy groups from the aromatic ring, with MAO-A serving as a primary metabolic enzyme.[7] Some involvement of liver enzymes (CYP450 family) has been suggested for related 2C analogs but remains unconfirmed for 2C-D specifically.[14]
Effects begin within 15–45 minutes of oral ingestion, with a total duration of 4–6 hours.[5] These timing parameters derive from Shulgin's self-experiments rather than controlled pharmacokinetic studies.
Neuroscience[edit]
Where it acts
2C-D's 5-HT₂A agonism engages the same cortical circuits characterized for other serotonergic psychedelics. These receptors are concentrated on neurons in the prefrontal cortex, where their activation increases excitatory signaling and disrupts the brain's normal filtering of sensory and cognitive input.[2][3] At the network level, serotonergic psychedelics typically disrupt default mode network integrity, reduce thalamic gating, and increase the overall complexity of brain activity — though no neuroimaging studies have been conducted with 2C-D.
The compound's weak receptor binding suggests these network-level disruptions are proportionally milder than those produced by higher-potency psychedelics such as LSD or psilocybin, consistent with 2C-D's subdued phenomenological profile at standard doses.
Why it matters
The entropic brain hypothesis proposes that psychedelics increase the disorder of spontaneous brain activity, expanding the range of accessible conscious states. The related REBUS model extends this, suggesting psychedelics loosen the brain's reliance on prior expectations to allow more flexible cognition.citation needed 2C-D's characterization as "pharmacological tofu" — potentiating other substances without strongly defining the experience — may represent a partial loosening of priors insufficient to generate full psychedelic phenomenology at standard doses.
Whether 2C-D's weak 5-HT₂A agonism is sufficient to promote structural neuroplasticity — dendritic growth and new synaptic connections mediated by BDNF and related signaling — has not been investigated.citation needed
- Does 2C-D produce measurable disruption of default mode network activity at standard oral doses, or is its receptor binding too weak to reach the threshold for network-level effects?
- Does the "potentiator" effect described by Shulgin reflect sub-threshold receptor occupancy that synergizes with co-administered psychedelics?
- How does the absence of the α-methyl group (distinguishing 2C-D from DOM) affect brain penetration, receptor residence time, and the character of neural effects?
Subjective Effects[edit]
2C-D's subjective character is defined more by what it lacks than what it produces. At standard doses, the experience is remarkably transparent — a gentle broadening of perceptual and emotional range without the forceful cognitive restructuring or visual intensity typical of most serotonergic psychedelics. Set and setting exert outsized influence precisely because the compound's own pharmacological signature is muted; the experience tends to amplify whatever mood and environment the individual brings to it.[5]
Compared to 2C-B, the most widely used 2C-series compound, 2C-D is substantially less visually active, less empathogenic, and more cognitively lucid at equivalent relative doses. Where 2C-B produces a distinctive sensory and emotional push, 2C-D operates closer to a psychedelic subthreshold state — Shulgin's "pharmacological tofu" — whose primary historical application was potentiating other substances rather than generating a standalone experience.
Effect Grid
At common doses (25–50 mg oral), 2C-D produces its characteristic profile: mild sensory enhancement, thought connectivity, emotional warmth, and facilitated communication. Visual effects are subtle — slight color alteration, gentle visual drifting, and enhanced pattern recognition — but do not dominate the experience. The cognitive space is clear and communicative, distinguishing 2C-D from more visually intense 2C-series compounds.
Physically, stimulation becomes noticeable: increased energy, mild jaw tension, pupil dilation, and slight cardiovascular elevation (heart rate, blood pressure). Appetite suppression is common. Duration is 4–6 hours, with 1–3 hours of mild residual stimulation.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual breathing · Tracers · Brightness alteration · Perspective distortion · Visual morphing · Touch enhancement · Symmetrical texture repetition · After-images · Visual diffraction · Auditory enhancement · Environmental patterning · Light sensitivity · Peripheral vision distortion · Sound sensitivity · Visual acuity enhancement · Depth perception distortion · Proprioceptive distortion · Spatial disorientation · Visual haze / noise · Synesthesia · Auditory distortion · Object transformations · Visual recursion · External hallucinations · Internal hallucinations
Visual morphing · Touch enhancement · Symmetrical texture repetition · After-images · Visual diffraction · Auditory enhancement · Environmental patterning · Light sensitivity · Peripheral vision distortion · Sound sensitivity · Visual acuity enhancement · Depth perception distortion · Proprioceptive distortion · Spatial disorientation · Visual haze / noise · Synesthesia · Auditory distortion · Object transformations · Visual recursion · External hallucinations · Internal hallucinations
Body high · Wakefulness · Tingling / electric sensations · Nausea · Appetite suppression · Dry mouth · Heart rate perception changes · Insomnia · Vibrations / buzzing · Dehydration sensation · Dizziness · Excessive sweating · Headache · Muscle tension · Restlessness · Abnormal heartbeat · Motor control enhancement
Nausea · Appetite suppression · Dry mouth · Heart rate perception changes · Insomnia · Vibrations / buzzing · Dehydration sensation · Dizziness · Excessive sweating · Headache · Muscle tension · Restlessness · Motor control enhancement
Aesthetic enhancement · Openness enhancement · Thought acceleration · Thought connectivity · Cognitive flexibility · Analysis enhancement · Creativity enhancement · Cognitive euphoria · Immersion enhancement · Increased nature relatedness · Multiple thought streams · Humor enhancement · Focus enhancement · Information processing enhancement · Thought organization · Memory suppression · Language enhancement · Motivation enhancement · Thought loops
Cognitive flexibility · Analysis enhancement · Creativity enhancement · Cognitive euphoria · Immersion enhancement · Increased nature relatedness · Multiple thought streams · Humor enhancement · Focus enhancement · Information processing enhancement · Thought organization · Memory suppression · Language enhancement · Motivation enhancement · Thought loops
Catharsis · Emotional lability · Empathy enhancement
Social connection · Sociability enhancement · Depersonalization · Boundary dissolution · Ego dissolution
Ego dissolution
Timeline
First alerts appear as a subtle shift in headspace — mild stimulation, faint brightening of colors, and a slight sense of anticipation. Effects may be barely distinguishable from placebo at this stage.
Effects build gradually: growing stimulation, emerging color enhancement, and increasing sociability. A mild body load — slight nausea or stomach awareness — may occur during this phase, particularly at higher doses.
Maximum intensity plateau with the clearest expression of 2C-D's character: enhanced sensory perception, facilitated communication, thought connectivity, and emotional openness. At common doses, this phase is gentle and lucid; at strong doses, visual drifting and color alteration become prominent.
Effects taper smoothly. Visual and cognitive effects diminish while mild stimulation and a residual sense of openness persist. Appetite begins to return.
Residual mild stimulation, slight mood elevation, and enhanced sensory appreciation may linger for several hours. Sleep may be slightly delayed if the experience occurred in the evening.
⚠ Do not drive or operate heavy machinery until after a full night of sleep following the experience.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- lsd · psilo · mesc
Toxicity
No lethal dose data exist for 2C-D, and no deaths attributed specifically to it alone appear in the published literature.[7] A clinical toxicology review of the 2C series documented five deaths across the class — involving 2C-E and 2C-I, not 2C-D.[7]
For the 2C series as a class, documented acute adverse presentations include[7]:
- Hallucinations, agitation, aggression, and dysphoria
- Elevated blood pressure and rapid heart rate
- Seizures
- Dangerously elevated body temperature
- Excited delirium (documented in fatalities involving other 2C compounds)
- Serotonin toxicity
2C-D's monoamine oxidase inhibitory activity adds a further risk: blocking this enzyme raises monoamine levels, amplifying cardiovascular stress and serotonin toxicity — especially in combination with other substances.[8]
Psychological risks
No controlled data on 2C-D-specific psychological risk exist. Class-level risks for serotonergic psychedelics include acute anxiety, panic reactions, and psychological destabilization in people with personal or family histories of psychotic disorders.
The relatively mild profile at standard doses suggests lower acute psychological risk than more potent psychedelics, though the poorly documented high-dose range carries unknown risk. inferred
Tolerance and dependence
Tolerance to serotonergic psychedelics develops rapidly after a single use. In mouse studies, tolerance to the related compound DOI developed within 24 hours of a single dose, with progressive tolerance over 4 days,[15] driven by downregulation in the frontal cortex.[15]
Cross-tolerance with LSD was confirmed in the same study,[15] supporting the expectation that all serotonin receptor psychedelics — including 2C-D — share it. No evidence of physical dependence, withdrawal, or compulsive use exists for 2C-D or any 2C-series compound.[7]
Drug Interactions
Serotonergic agents
Combining 2C-D with substances that raise serotonin — SSRIs, SNRIs, tramadol, classical MAOIs — risks serotonin syndrome. 2C-D contributes through two pathways: direct serotonin receptor activation and MAO inhibition.[8]
Tramadol is a particularly dangerous combination. It blocks the SERT, raising synaptic serotonin;[16] combined with 2C-D's receptor agonism and MAO inhibition,[8] these pathways converge. Tramadol fatalities in combination with MAOIs are documented,[17] and tramadol additionally lowers the seizure threshold.
Classical MAOIs produce dual MAO inhibition alongside direct serotonin receptor agonism[8][17] — a high-risk combination for serotonin toxicity. 2C-series compounds have been documented in serotonin syndrome case reports when combined with serotonergic agents.[18]
Contraindications
7 knownNo published contraindications specific to 2C-D exist. The following are inferred from its pharmacological class and MAO inhibitory propertiesinferred:
- Personal or family history of psychotic disorders — serotonin receptor activation can precipitate or worsen psychotic episodes in vulnerable individuals
- Bipolar disorder — psychedelic use carries risk of triggering manic episodes
- Heart conditions — elevated blood pressure and rapid heart rate are documented for the 2C-series class[7] and may be clinically significant with pre-existing cardiovascular disease
- Concurrent MAOI use — dual MAO inhibition plus serotonin receptor agonism creates high risk for serotonin toxicity[8]
- Concurrent serotonergic medication — SSRIs, SNRIs, tramadol, and other serotonin-raising agents create compounding risk
- Seizure disorders — seizures are documented among 2C-series adverse events[7]
- Pregnancy — no reproductive toxicity data exist; standard precautionary contraindication applies
Harm Reduction[edit]
Forms & Identification
2C-D circulates almost exclusively as a white crystalline powder or pressed tablets. Because 2C-series compounds are visually indistinguishable in powder form, reagent testing is essential — mislabeled material carrying a more potent compound like 2C-E or 2C-P poses the most immediate identification risk. A milligram-precision scale is necessary for accurate dosing; never estimate powder doses by eye.
Guidelines
- Test every batch with at least two reagent kits before use.
- Weigh doses with a milligram-precision scale — never estimate powder by eye.
- Start with a low dose to assess individual sensitivity before exploring higher ranges.
- Choose a calm, familiar environment with a trusted sitter present, especially for first experiences.
- Avoid dosing on a full stomach to reduce nausea during onset; have light food and water available.
- Allow at least 8 hours free of obligations for the full experience and aftereffects.
- Do not redose during the first 90 minutes; onset can be slow and redosing before peak risks unexpectedly strong effects.
Set & Setting
2C-D's transparent, context-sensitive character means set and setting shape the experience more than the compound itself. A calm, familiar environment with a trusted person present provides the best foundation. Avoid dosing during periods of emotional distress, sleep deprivation, or interpersonal conflict — the compound tends to amplify whatever state is brought to it.
Aftercare & integration. The mild character of 2C-D at standard doses typically produces a gentle return to baseline with minimal aftereffects. Allow the rest of the day for quiet recovery — light meals, hydration, and rest. If the experience surfaced emotional material or unexpected insights, journaling within 24 hours captures details that fade quickly.
If the experience was distressing or confusing, talking with a trusted friend or integration-focused therapist can help process what arose. Repeated difficult experiences may warrant professional support rather than further use.
Recovery & Support
2C-D does not produce physical dependence, and compulsive use patterns are not documented for any 2C-series compound. If psychedelic use is becoming a pattern to avoid difficult emotions or obligations, or if frequency is escalating, these are signals to reassess.
Support resources include psychedelic integration circles, harm reduction organizations, and therapists experienced with substance use. The Fireside Project (62-FIRESIDE) offers free, confidential support for people processing psychedelic experiences.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency
Most 2C-D experiences at standard doses resolve without medical intervention. Seek immediate help if any of the following occur:
- Seizure activity or loss of consciousness
- Chest pain or difficulty breathing
- Body temperature noticeably elevated to the touch
- Severe confusion, inability to recognize surroundings or communicate
- Self-harm behavior or complete disconnection from reality
Immediate steps
- 1. Call emergency services if any red flags above are present.
- 2. Place an unconscious person in the recovery position (on their side, airway clear).
- 3. Move the person to a cool, quiet space. Remove excess clothing if overheating.
- 4. Do not restrain unless there is immediate danger of self-harm.
- 5. Stay with the person and speak calmly until help arrives.
What to tell the dispatcher
Provide the substance name (2C-D), estimated amount taken, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
2C-D is a controlled substance in multiple jurisdictions, explicitly scheduled in the United States as Schedule I under the synthetic Drug Abuse Prevention Act of 2012.[6] International scheduling varies, with most jurisdictions classifying 2C-D under blanket phenethylamine prohibitions or specific substance listings.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Explicitly named in the Synthetic Drug Abuse Prevention Act of 2012 (FDASIA, P.L. 112-144), signed July 9, 2012[6] |
| United Kingdom | Class A, Schedule 1 (Misuse of Drugs Act) | Classified under 2002 amendment encompassing all PiHKAL phenethylamines[4] |
| Canada | Schedule III (Controlled Drugs and Substances Act) | Listed October 31, 2016[4] |
| Australia | Prohibited | Blanket prohibition on substituted phenethylamines under analog scheduling provisions[4] |
European Union country-by-country scheduling was not confirmed from primary legal databases. 2C-D is reported to be controlled across most EU member states, but specific schedules require verification. citation needed
Legal status changes frequently and varies by jurisdiction. This information is not legal advice — verify current law in your location before drawing conclusions.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- lsd · psilo · mesc
Toxicity
No lethal dose data have been established for 2C-D in any species, and no deaths or serious adverse events attributed specifically to 2C-D alone appear in the published literature.[7] A clinical toxicology review documented at least five deaths involving 2C-series compounds overall, but these involved other members — primarily 2C-E and 2C-I — with no 2C-D-specific fatalities reported.[7]
For the 2C series as a class, documented acute adverse presentations include[7]:
- Hallucinations, agitation, aggression, and dysphoria
- Elevated blood pressure and rapid heart rate
- Seizures
- Dangerously elevated body temperature
- Excited delirium (documented in fatalities involving other 2C compounds)
- Serotonin toxicity
2C-D's demonstrated monoamine oxidase inhibitory potential[8] adds an additional toxicological mechanism: inhibiting monoamine oxidase elevates brain monoamine levels, which can intensify cardiovascular stress, agitation, and serotonin toxicity — particularly in combination with other serotonergic or stimulant substances.
Psychological risks
No controlled data on psychological risk specific to 2C-D exist. Class-level risks for serotonergic psychedelics include acute psychological distress, anxiety, panic reactions, and psychological destabilization in individuals with personal or family histories of psychotic disorders.
The relatively mild profile of 2C-D at standard doses suggests lower acute psychological risk than more potent psychedelics, though the poorly documented high-dose range carries unknown risk. inferred
Tolerance and dependence
Tolerance develops rapidly after a single use of any serotonergic psychedelic. In mouse studies, tolerance to the effects of the serotonin 2A receptor agonist DOI developed within 24 hours of a single dose, with progressive tolerance over 4 days of repeated administration.[15] This tolerance is driven by downregulation in the frontal cortex and is independent of β-arrestin-2.[15] Cross-tolerance between DOI and LSD was confirmed in the same study, supporting the expectation that all 5-HT₂A agonist psychedelics — including 2C-D — share cross-tolerance.
No evidence of physical dependence, withdrawal, or compulsive redosing exists for 2C-D or any 2C-series compound.[7]
Drug Interactions
Serotonergic agents
Combining 2C-D with other serotonergic substances carries risk of serotonin toxicity. 2C-D contributes through two mechanisms: direct 5-HT₂A agonism and MAO inhibition.[8] Substances that raise serotonin levels through complementary pathways — including SSRIs, SNRIs, tramadol, and classical MAOIs — create conditions for serotonin syndrome when combined with 2C-D.
Tramadol is classified as a dangerous interaction. Tramadol blocks the SERT, raising synaptic serotonin.[16] Combined with 2C-D's receptor agonism and MAO inhibition,[8] this produces converging serotonergic stimulation. Tramadol fatalities in combination with MAOIs are documented.[17] Tramadol also lowers the seizure threshold, compounding the seizure risk associated with 2C-series compounds.
Classical MAOIs combined with 2C-D would produce dual MAO inhibition alongside direct 5-HT₂A agonism — a high-risk combination for serotonin toxicity.[8][17]
2C-series compounds have been documented in serotonin syndrome case reports when combined with other serotonergic agents.[18]
Contraindications
7 knownNo published contraindications specific to 2C-D exist. The following are inferred from its pharmacological class and MAO inhibitory propertiesinferred:
- Personal or family history of psychotic disorders — 5-HT₂A agonism can precipitate or worsen psychotic episodes in vulnerable individuals
- Bipolar disorder — psychedelic use carries risk of triggering manic episodes
- Heart conditions — elevated blood pressure and rapid heart rate are documented for the 2C-series class[7] and may be clinically significant in those with pre-existing cardiovascular disease
- Concurrent MAOI use — dual MAO inhibition plus 5-HT₂A agonism creates high risk for serotonin toxicity[8]
- Concurrent serotonergic medication — SSRIs, SNRIs, tramadol, and other serotonin-elevating agents create compounding risk
- Seizure disorders — seizures are documented among 2C-series adverse events[7]
- Pregnancy — no reproductive toxicity data exist; standard precautionary contraindication applies
Harm Reduction[edit]
Forms & Identification
2C-D circulates almost exclusively as a white crystalline powder or pressed tablets. Because 2C-series compounds are visually indistinguishable from each other in powder form, reagent testing is essential — mislabeled material carrying a more potent compound like 2C-E or 2C-P poses the most immediate identification risk. A milligram-precision scale is critical for accurate dosing; never estimate powder doses by eye.
Guidelines
- Test every batch with at least two reagent kits before use.
- Weigh doses with a milligram-precision scale — never estimate powder by eye.
- Start with a low dose to assess individual sensitivity before exploring higher ranges.
- Choose a calm, familiar environment with a trusted sitter present, especially for first experiences.
- Avoid dosing on a full stomach to reduce nausea during onset; have light food and water available.
- Clear your schedule — allow at least 8 hours free of obligations for the full experience and aftereffects.
- Do not redose during the first 90 minutes; onset can be slow and redosing before peak risks unexpectedly strong effects.
Set & Setting
2C-D's transparent, context-sensitive character means set and setting shape the experience more than the compound itself. A calm, familiar environment with a trusted person present provides the best foundation. Avoid dosing during periods of emotional distress, sleep deprivation, or interpersonal conflict — the compound tends to amplify whatever state the individual brings to it.
Aftercare & integration. The mild character of 2C-D at standard doses typically produces a gentle return to baseline with minimal aftereffects. Allow the rest of the day for quiet recovery — light meals, hydration, and rest. If the experience raised emotional material or unexpected insights, journaling within 24 hours captures details that fade quickly.
For experiences that were distressing or confusing, talking with a trusted friend or integration-focused therapist can help process what arose. Repeated difficult experiences may warrant professional support rather than further use.
Recovery & Support
2C-D does not produce physical dependence, and compulsive use patterns are not documented for any 2C-series compound. If psychedelic use is becoming a pattern used to avoid difficult emotions or obligations, or if frequency is escalating, these are signals to reassess the relationship with the substance.
Support resources include psychedelic integration circles, harm reduction organizations, and therapists experienced with substance use. The Fireside Project (62-FIRESIDE) offers free, confidential support for people processing psychedelic experiences.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency
Most 2C-D experiences at standard doses resolve without medical intervention. Seek immediate help if any of the following occur:
- Seizure activity or loss of consciousness
- Chest pain or difficulty breathing
- Body temperature noticeably elevated to the touch
- Severe confusion, inability to recognize surroundings or communicate
- Self-harm behavior or complete disconnection from reality
Immediate steps
- 1. Call emergency services if any red flags above are present.
- 2. Place an unconscious person in the recovery position (on their side, airway clear).
- 3. Move the person to a cool, quiet space. Remove excess clothing if overheating.
- 4. Do not restrain unless there is immediate danger of self-harm.
- 5. Stay with the person and speak calmly until help arrives.
What to tell the dispatcher
Provide the substance name (2C-D), estimated amount taken, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
2C-D is controlled as a scheduled substance in multiple jurisdictions. In the United States, it was explicitly listed in Schedule I through the synthetic Drug Abuse Prevention Act of 2012.[6] Prior to 2012, 2C-D was not specifically scheduled under federal law, though it may have been subject to prosecution under the Federal Analogue Act if intended for human consumption.
International scheduling varies, with most jurisdictions classifying 2C-D under blanket phenethylamine prohibitions or specific substance listings.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Explicitly named in the Synthetic Drug Abuse Prevention Act of 2012 (FDASIA, P.L. 112-144), signed July 9, 2012[6] |
| United Kingdom | Class A, Schedule 1 (Misuse of Drugs Act) | Classified under 2002 amendment encompassing all PiHKAL phenethylamines[4] |
| Canada | Schedule III (Controlled Drugs and Substances Act) | Listed October 31, 2016[4] |
| Australia | Prohibited | Blanket prohibition on substituted phenethylamines under analog scheduling provisions[4] |
European Union country-by-country scheduling was not confirmed from primary legal databases during this research cycle. 2C-D is reported to be controlled across most EU member states, but specific schedules and enactment dates require verification. citation needed
Frequently asked questions
How long does 2C-D last?
Total duration by route of administration — Oral: 4 – 6 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for 2C-D?
Psychedex publishes a dosage table for 2C-D on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with 2C-D?
The highest-severity documented interactions for 2C-D: MAOIs (Lethal), Buspirone (Dangerous), Dopamine agonists (Dangerous), GHB, Baclofen (Dangerous), GHB, GBL (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is 2C-D addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for 2C-D: tolerance builds rapid; full reset takes 7 days; cross-tolerance develops with lsd, psilocybin, mescaline, 2c-b, 2c-e, 2c-i, dom, doi. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2] ^abcAghajanian GK, Marek GJ (1999) Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release — Brain Research PMID:10216183
- [3] ^abcAghajanian GK, Marek GJ (1999) Serotonin and hallucinogens — Neuropsychopharmacology PMID:10432484
- [4]
- [5]
- [6]
references
- [1]
- [2] ^abcAghajanian GK, Marek GJ (1999) Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release — Brain Research PMID:10216183
- [3] ^abcAghajanian GK, Marek GJ (1999) Serotonin and hallucinogens — Neuropsychopharmacology PMID:10432484
- [4]
- [5]
- [6]